| Primary |
| Idiopathic Thrombocytopenic Purpura |
22.3% |
| Product Used For Unknown Indication |
12.1% |
| Off Label Use |
10.0% |
| Drug Use For Unknown Indication |
8.4% |
| Kawasaki's Disease |
4.7% |
| Immunodeficiency Common Variable |
4.3% |
| Premedication |
4.3% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
4.0% |
| Evans Syndrome |
3.3% |
| Guillain-barre Syndrome |
3.2% |
| Thrombocytopenia |
3.1% |
| Cardiomyopathy Neonatal |
3.0% |
| Prophylaxis |
2.9% |
| Primary Immunodeficiency Syndrome |
2.6% |
| Demyelinating Polyneuropathy |
2.2% |
| Antiemetic Supportive Care |
2.1% |
| Gastrooesophageal Reflux Prophylaxis |
2.0% |
| Foetal Exposure Timing Unspecified |
1.9% |
| Hypogammaglobulinaemia |
1.9% |
| Histiocytosis Haematophagic |
1.6% |
|
| Neutropenia |
35.0% |
| Maternal Exposure During Pregnancy |
5.9% |
| Vomiting |
5.6% |
| Pulmonary Embolism |
5.3% |
| Drug Exposure During Pregnancy |
5.0% |
| Anaphylactic Reaction |
4.6% |
| Pyrexia |
4.3% |
| Drug Intolerance |
3.1% |
| Haemorrhage Intracranial |
3.1% |
| Infusion Related Reaction |
3.1% |
| Renal Failure Acute |
3.1% |
| Cerebrovascular Accident |
2.8% |
| Haemolysis |
2.8% |
| Haemolytic Anaemia |
2.8% |
| Meningitis Aseptic |
2.8% |
| Drug Ineffective |
2.5% |
| Tremor |
2.5% |
| Renal Failure |
2.2% |
| Anaphylactic Shock |
1.9% |
| Coronary Artery Aneurysm |
1.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
18.1% |
| Product Used For Unknown Indication |
16.9% |
| Idiopathic Thrombocytopenic Purpura |
8.1% |
| Off Label Use |
7.2% |
| Evans Syndrome |
6.2% |
| Immunosuppression |
5.2% |
| Bacteraemia |
3.7% |
| Histiocytosis Haematophagic |
3.3% |
| Kawasaki's Disease |
3.2% |
| Hypertension |
3.1% |
| Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
3.0% |
| Prophylaxis |
3.0% |
| Autoimmune Disorder |
2.7% |
| Premedication |
2.6% |
| Pyoderma Gangrenosum |
2.6% |
| Infection |
2.4% |
| Pancytopenia |
2.3% |
| Cytomegalovirus Infection |
2.1% |
| Sjogren's Syndrome |
2.1% |
| Dermatomyositis |
1.9% |
|
| Hepatitis B Dna Assay Positive |
10.3% |
| Maternal Exposure During Pregnancy |
8.2% |
| Pyrexia |
8.2% |
| Rash |
7.8% |
| Vomiting |
7.8% |
| Tricuspid Valve Incompetence |
6.0% |
| Drug Exposure During Pregnancy |
5.6% |
| Hepatitis C Rna Positive |
5.6% |
| Toxic Epidermal Necrolysis |
5.6% |
| Anaphylactic Reaction |
5.2% |
| Haemolytic Anaemia |
3.9% |
| Weight Decreased |
3.4% |
| Haemorrhage Intracranial |
3.0% |
| Thrombocytopenia |
3.0% |
| Urinary Tract Infection |
3.0% |
| Viral Infection |
3.0% |
| Cardiotoxicity |
2.6% |
| Meningitis Aseptic |
2.6% |
| Pulmonary Embolism |
2.6% |
| Respiratory Failure |
2.6% |
|
| Concomitant |
| Drug Use For Unknown Indication |
32.5% |
| Idiopathic Thrombocytopenic Purpura |
17.3% |
| Product Used For Unknown Indication |
7.0% |
| Prophylaxis |
5.5% |
| Infection Prophylaxis |
4.3% |
| Systemic Lupus Erythematosus |
3.0% |
| Pain |
2.8% |
| Multiple Sclerosis |
2.7% |
| Hypertension |
2.7% |
| Fistulogram |
2.6% |
| Multiple Myeloma |
2.6% |
| Kawasaki's Disease |
2.6% |
| Stem Cell Transplant |
2.4% |
| Pneumonia |
2.3% |
| Chronic Lymphocytic Leukaemia |
2.1% |
| Prophylaxis Against Graft Versus Host Disease |
2.1% |
| Sepsis |
1.9% |
| Rheumatoid Arthritis |
1.3% |
| Premedication |
1.2% |
| Chronic Myeloid Leukaemia |
1.2% |
|
| White Blood Cell Count Decreased |
10.1% |
| Death |
9.5% |
| Thrombocytopenia |
8.2% |
| Sepsis |
7.6% |
| Vomiting |
7.4% |
| Pneumonia |
5.9% |
| Drug Ineffective |
5.7% |
| Skin Tightness |
5.3% |
| Renal Impairment |
4.8% |
| Thrombotic Microangiopathy |
4.2% |
| Pyrexia |
4.0% |
| Septic Shock |
4.0% |
| Urinary Tract Infection |
3.4% |
| Systemic Inflammatory Response Syndrome |
3.2% |
| Progressive Multifocal Leukoencephalopathy |
2.9% |
| Renal Failure |
2.9% |
| Renal Failure Chronic |
2.9% |
| Liver Disorder |
2.7% |
| Respiratory Failure |
2.7% |
| Toxic Epidermal Necrolysis |
2.7% |
|
